Advertisement
ABBV vs BMY
Which Stock Would AI Choose? AbbVie (ABBV) vs. Bristol-Myers Squibb (BMY) Stock Comparison
Key Takeaways
- AbbVie (ABBV) demonstrates stronger recent revenue growth driven by its immunology portfolio, while Bristol-Myers Squibb (BMY) offers a more attractive valuation with a higher dividend yield.
- Both companies operate in the biopharmaceutical sector, facing patent expirations but advancing pipelines in oncology, immunology, and neuroscience.
- ABBV stock has shown resilience with gains in recent market activity supported by acquisitions and positive clinical data, whereas BMY has experienced more volatility amid broader sector pressures.
- Market sentiment favors ABBV for growth momentum, while BMY appeals to value-oriented investors seeking income stability.
- Relative performance highlights trade-offs between premium growth assets at ABBV and discounted positioning at BMY.
Introduction
AbbVie (ABBV) and Bristol-Myers Squibb (BMY) represent two major players in the biopharmaceutical industry, each navigating patent cliffs, pipeline innovation, and evolving market dynamics. This comparison examines their business models, recent stock behavior, and relative positioning to assist institutional investors, portfolio managers, and individual traders evaluating healthcare exposure. The analysis draws on verifiable financial metrics and developments from recent weeks to provide a balanced view relevant for those assessing dividend sustainability, growth catalysts, and sector allocation strategies.
ABBV Overview and Recent Performance
AbbVie (ABBV) is a research-based biopharmaceutical company focused on immunology, oncology, neuroscience, and aesthetics. In recent market activity, the stock has traded in a range near $260–$267 amid positive clinical updates and the completion of its acquisition of Apogee Therapeutics. Second-quarter 2026 results showed net revenues of $16.99 billion, up 10.2% year-over-year, fueled by double-digit growth in Skyrizi and Rinvoq within the immunology portfolio. Sentiment has been supported by Phase 3 data for etentamig in multiple myeloma and atogepant in menstrual migraine prevention, alongside the Apogee deal that expands the late-stage immunology pipeline despite modest near-term earnings dilution.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY) develops and commercializes medicines in oncology, hematology, immunology, and cardiovascular disease. The stock has fluctuated around $62–$68 in recent weeks, reflecting mixed momentum as growth brands gain traction while legacy products face competition. Second-quarter 2026 revenue reached approximately $13 billion, up 5.7%, with earnings per share exceeding expectations. Positive data on Sotyktu for psoriatic arthritis and ongoing Eliquis demand have contributed to sentiment, though the shares have seen some pullback over the past month amid sector rotation and broader valuation considerations.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from hundreds available across thousands of tickers. Only those demonstrating the strongest suitability for prevailing market conditions, including consistent trend capture and risk-adjusted returns, earn placement in this section. Available bots exhibit varied trading styles, strategies, timeframes, and performance statistics, with many showing win rates in the 55–75% range and differing drawdown profiles depending on their underlying algorithms. This resource allows traders to explore automated approaches tailored to equities such as ABBV and BMY. Explore the full selection on the Trending AI Robots page for data-driven insights.
Head-to-Head Comparison
AbbVie (ABBV) and Bristol-Myers Squibb (BMY) differ markedly in scale and focus. ABBV maintains a larger market capitalization near $466 billion and emphasizes high-growth immunology assets with operational revenue expansion exceeding 9% recently. BMY, valued at approximately $129 billion, offers broader oncology exposure through products like Opdivo while delivering a dividend yield near 4%. Recent momentum favors ABBV due to pipeline catalysts and acquisition activity, whereas BMY trades at a lower forward price-to-earnings multiple around 9–10x compared with ABBV’s premium valuation. Risk factors include patent expirations for both, though ABBV’s growth portfolio has shown greater resilience in recent periods. Sector sentiment reflects ABBV’s stronger relative performance versus BMY’s value appeal amid healthcare volatility.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings momentum, and pipeline positioning in recent market activity, Tickeron’s AI would currently assign a higher probabilistic preference to AbbVie (ABBV). Its stronger revenue trajectory and clinical catalysts provide more consistent signals than the mixed performance at Bristol-Myers Squibb (BMY), though both remain subject to sector-specific risks and valuation shifts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and BMY is a Buy.
| ABBV | BMY | ABBV / BMY | |
| Capitalization | 466B | 129B | 361% |
| EBITDA | 19.5B | 16.8B | 116% |
| Gain YTD | 18.488 | 20.015 | 92% |
| P/E Ratio | 74.56 | 13.89 | 537% |
| Revenue | 64.4B | 49.2B | 131% |
| Total Cash | 6.57B | 11.1B | 59% |
| Total Debt | 70.8B | 45.1B | 157% |
ABBV | BMY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 16 Undervalued | 39 Fair valued | |
PROFIT vs RISK RATING 1..100 | 4 | 85 | |
SMR RATING 1..100 | 1 | 22 | |
PRICE GROWTH RATING 1..100 | 41 | 43 | |
P/E GROWTH RATING 1..100 | 78 | 71 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV's Valuation (16) in the Pharmaceuticals Major industry is in the same range as BMY (39). This means that ABBV’s stock grew similarly to BMY’s over the last 12 months.
ABBV's Profit vs Risk Rating (4) in the Pharmaceuticals Major industry is significantly better than the same rating for BMY (85). This means that ABBV’s stock grew significantly faster than BMY’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as BMY (22). This means that ABBV’s stock grew similarly to BMY’s over the last 12 months.
ABBV's Price Growth Rating (41) in the Pharmaceuticals Major industry is in the same range as BMY (43). This means that ABBV’s stock grew similarly to BMY’s over the last 12 months.
BMY's P/E Growth Rating (71) in the Pharmaceuticals Major industry is in the same range as ABBV (78). This means that BMY’s stock grew similarly to ABBV’s over the last 12 months.
| ABBV | BMY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 44% | 2 days ago 55% |
| Stochastic ODDS (%) | 2 days ago 47% | 2 days ago 53% |
| Momentum ODDS (%) | 2 days ago 65% | 2 days ago 54% |
| MACD ODDS (%) | 2 days ago 61% | 2 days ago 45% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 53% |
| TrendMonth ODDS (%) | 2 days ago 55% | 2 days ago 55% |
| Advances ODDS (%) | 8 days ago 61% | 20 days ago 57% |
| Declines ODDS (%) | 15 days ago 46% | 6 days ago 53% |
| BollingerBands ODDS (%) | 2 days ago 54% | 2 days ago 66% |
| Aroon ODDS (%) | N/A | 2 days ago 55% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 3 FA rating(s) are green while BMY’s FA Score has 1 green FA rating(s).
- ABBV’s FA Score: 3 green, 2 red.
- BMY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 5 TA indicator(s) are bullish while BMY’s TA Score has 3 bullish TA indicator(s).
- ABBV’s TA Score: 5 bullish, 3 bearish.
- BMY’s TA Score: 3 bullish, 7 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +1.04% price change this week, while BMY (@Pharmaceuticals: Major) price change was -2.31% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.29%. For the same industry, the average monthly price growth was -4.59%, and the average quarterly price growth was +16.77%.
Reported Earning Dates
ABBV is expected to report earnings on Oct 23, 2026.
BMY is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+3.29% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with BMY. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +0.20% | ||
| BMY - ABBV | 51% Loosely correlated | -0.70% | ||
| NVS - ABBV | 50% Loosely correlated | +0.43% | ||
| JNJ - ABBV | 49% Loosely correlated | -0.19% | ||
| MRK - ABBV | 46% Loosely correlated | +1.79% | ||
| AMGN - ABBV | 46% Loosely correlated | +1.95% | ||
More | ||||